Nisa Investment Advisors LLC Sells 1,221 Shares of Revolution Medicines, Inc. $RVMD

Nisa Investment Advisors LLC cut its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 38.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,989 shares of the company’s stock after selling 1,221 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Revolution Medicines were worth $73,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Harbor Capital Advisors Inc. boosted its stake in Revolution Medicines by 64.7% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 58,323 shares of the company’s stock worth $2,146,000 after purchasing an additional 22,906 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Revolution Medicines during the first quarter valued at approximately $502,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Revolution Medicines by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 109,004 shares of the company’s stock worth $3,870,000 after buying an additional 6,877 shares in the last quarter. Atle Fund Management AB boosted its position in shares of Revolution Medicines by 49.7% during the second quarter. Atle Fund Management AB now owns 82,275 shares of the company’s stock worth $3,027,000 after acquiring an additional 27,314 shares during the last quarter. Finally, Intech Investment Management LLC boosted its position in shares of Revolution Medicines by 48.8% during the first quarter. Intech Investment Management LLC now owns 107,628 shares of the company’s stock worth $3,806,000 after acquiring an additional 35,300 shares during the last quarter. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Revolution Medicines Trading Up 1.3%

RVMD stock opened at $59.34 on Thursday. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40. The stock has a market capitalization of $11.09 billion, a price-to-earnings ratio of -13.19 and a beta of 1.25. The company has a quick ratio of 11.79, a current ratio of 11.79 and a debt-to-equity ratio of 0.13. The firm’s fifty day simple moving average is $47.71 and its two-hundred day simple moving average is $41.67.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same period in the previous year, the company posted ($0.94) EPS. As a group, analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Jack Anders sold 2,320 shares of the stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $45.82, for a total value of $106,302.40. Following the sale, the chief financial officer directly owned 110,994 shares in the company, valued at approximately $5,085,745.08. This represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Lin Wei sold 2,160 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $45.82, for a total value of $98,971.20. Following the sale, the insider directly owned 88,339 shares of the company’s stock, valued at $4,047,692.98. This represents a 2.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 188,033 shares of company stock valued at $8,456,208 over the last quarter. Corporate insiders own 8.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on RVMD. The Goldman Sachs Group lifted their price target on shares of Revolution Medicines from $65.00 to $73.00 and gave the company a “buy” rating in a report on Friday, September 12th. Wells Fargo & Company raised their price objective on Revolution Medicines from $67.00 to $70.00 and gave the company an “overweight” rating in a research report on Thursday, September 11th. Mizuho began coverage on Revolution Medicines in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $90.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $77.00 price target on shares of Revolution Medicines in a research note on Friday, October 17th. Finally, Piper Sandler started coverage on Revolution Medicines in a report on Monday, August 18th. They set an “overweight” rating and a $75.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $77.47.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.